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Inate immunity: Turning off natural killers
John Imboden
Inhibitory receptors specific for class I molecules of the
major histocompatibility complex regulate the cytolytic
activity of natural killer cells. Recent studies suggest
that recruitment of the protein tyrosine phosphatase
SHP-1 enables these receptors to block natural killing.
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Natural killer (NK) cells are large granular lymphocytes
which bring about cell-mediated cytotoxicity and produce
cytokines following interaction with a range of target cells,
including tumor cells and virus-infected cells [1]. Unlike
the cytotoxic responses of T cells, the cytolytic activity of
NK cells against a particular target is spontaneous and
independent of prior sensitization — hence the term
‘natural’ killing. NK cells are a component of the innate
immune system, with a role in the early host defense
against certain viral infections [1]. NK-cell-derived
cytokines, such as g interferon, also may help regulate the
development of a specific immune response, acting as a
bridge between the innate and adaptive immune systems.
Once dismissed as the poor relations of the more illustrious
T cell, NK cells are now in the immunological limelight.
Remarkably, this new interest in NK cells has been pro-
pelled not by advances in understanding how these cells
are activated but, rather, by insights into the mechanisms
that turn them off.
Whether a target cell triggers the cytolytic machinery of an
NK cell probably depends on a complex interplay
between stimulatory and inhibitory signals. Considerable
efforts from many laboratories have failed so far to define
clearly the cell-surface receptors responsible for transduc-
ing activation signals to NK cells upon recognition of
target cells. Ligation of CD16 — a receptor for the con-
stant region (Fcg) of immunoglobulin G molecules — or
antibody-mediated stimulation of a number of surface
molecules, including CD2, NKRP-1 and CD69, triggers
NK cytolytic activity, but none of these has emerged as a
consensus candidate for ‘the NK cell receptor’ — the
equivalent of the antigen receptors on T and B cells [2].
Although the receptors involved in target-cell recognition
by NK cells remain elusive, there has been some progress
in elucidating the signaling events involved in NK-cell
activation. Not surprisingly, these are similar to those used
by the antigen receptors of T and B cells, involving the
stimulation of protein tyrosine kinases and the consequent
activation of signaling cascades, including the phospholi-
pase C pathway. Thus, interactions with sensitive target
cells trigger tyrosine phosphorylation, phosphoinositide
turnover and increases in the concentrations of cytoplasmic
free calcium ([Ca2+]i) within NK cells [3].
Inhibitory signals play a prominent role in the regulation
of NK cells, as demonstrated by the observation of a
decade ago that, broadly speaking, susceptibility to NK-
cell-mediated cytotoxicity correlates inversely with
expression on the target cell of class I molecules of the
major histocompatibility complex (MHC) [4]. The identi-
fication of inhibitory receptors specific for MHC class I
molecules has significantly advanced our understanding of
NK-cell biology (reviewed in [2,5]). 
Human NK cells express members of at least two families
of inhibitory receptors. The p58 inhibitory receptors
recognize polymorphic determinants of HLA-C mole-
cules, whereas the p70 inhibitory receptors distinguish
among allelic subsets of HLA-B molecules [5]. The inter-
action of an inhibitory receptor with its HLA ligand on a
target cell blocks killing of that target. NK cell clones from
a given individual are heterogeneous with respect to
inhibitory receptor expression, and the target-cell speci-
ficity of an NK cell clone is determined, at least in part, by
the particular complement of inhibitory receptors that it
expresses [5].
Studies of mouse NK cells have led to the identification of
a completely distinct group of NK-cell inhibitory recep-
tors: the Ly49 family [2,5]. Unlike the human inhibitory
receptors, which are members of the immunoglobulin
superfamily, the Ly49 molecules are type II integral mem-
brane proteins — having intracellular amino termini —
and their extracellular domains resemble C-type lectins
[2,5]. Although structurally unrelated to the human
inhibitory receptors, Ly49 molecules also recognize poly-
morphic MHC class I determinants and inhibit lysis of
targets expressing their cognate ligands [2,5]. It is not clear
if there are subtle, but important, differences in the func-
tions of human inhibitory receptors and Ly49 molecules,
or whether human and mouse NK cells use these very dif-
ferent structures to the same end. The first possibility pre-
dicts the existence of immunoglobulin-like inhibitory
receptors on mouse NK cells and of Ly49 homologues on
human cells, but these have yet to be identified.
Our understanding of the signals that turn lymphocytes
off has lagged well behind insights into the processes that
turn them on, but recent studies of the Src homology 2
(SH2) domain-containing tyrosine phosphatase SHP-1 —
also known as SHP, HCP, SHPTP-1 or PTP1C — have
started to narrow the gap [6]. Mutations in the gene that
encodes SHP-1 account for the widespread hematological
and immunological abnormalities of motheaten (me) mice,
and SHP-1 is now known to play a critical role in the inhi-
bition of a range of receptors on hematopoietic cells.
Tyrosine phosphorylation of key residues within a recep-
tor, or within molecules that associate with a receptor, can
create a recognition site for the SH2 domains of SHP-1,
leading to recruitment of SHP-1, the activation of its phos-
phatase activity and inhibition of receptor signaling [6].
Direct binding of SHP-1 to the erythropoietin receptor,
for example, downregulates the signaling response to ery-
thropoietin. SHP-1 also is involved in the negative feed-
back loop by which immune complexes of antigen and
immunoglobulin inhibit B cells specific for the antigen [6]. 
Stimulation of the B-cell antigen receptor leads to the
tyrosine phosphorylation of the Fc receptor FcgRIIB,
which in turn triggers the binding of SHP-1 to FcgRIIB.
The co-clustering of the B-cell receptor and FcgRIIB by
immune complexes inhibits B-cell receptor signaling by
bringing the phosphatase into proximity with the B-cell
receptor. Recruitment of SHP-1 is also likely to explain
how CD22, a cell-surface molecule which associates with
the B-cell receptor and is tyrosine phosphorylated follow-
ing B-cell receptor stimulation, downregulates B-cell
receptor signaling [6].
Not surprisingly, efforts to unravel the signaling mecha-
nism of NK-cell inhibitory receptors have focused on the
possible involvement of SHP-1, and the initial results are
encouraging.  Stimulation of human p58 inhibitory recep-
tors, either by crosslinking antibodies or by exposure of
NK cells to resistant target cells expressing an appropriate
HLA-C molecule, triggers the tyrosine phosphorylation of
p58 and an association between p58 and SHP-1 [7,8].
Overexpression of a catalytically inactive mutant form of
SHP-1 prevents p58-mediated inhibition of target cell
lysis, arguing that the phosphatase activity of SHP-1 is
critical for p58 function [7].
The tyrosine residues of CD22 and FcgRIIB which, when
phosphorylated, recruit SHP-1 lie within critical
sequences termed immunoreceptor tyrosine-based
inhibitory motifs (ITIMs) [6–9]. Interestingly, the CD22
and FcgRIIB ITIMs share a consensus motif (V/IxYxxL)
with sequences from the cytoplasmic domains of the p58
and p70 human inhibitory receptors [7–9]. Phosphorylated
peptides corresponding to the sequences from p58 bind
fusion proteins containing the SHP-1 SH2 domains and
activate SHP-1 phosphatase activity in vitro, suggesting
that these function as ITIMs [7–9].
SHP-1 may also be involved in the function of the lectin-
like Ly49 molecules. The ability of Ly49A to inhibit
killing is impaired in Ly49A+ NK cells obtained from
mev/v mice, which express reduced levels of SHP-1 (M.
Nakamura, J. Ryan and W.E. Seaman, personal communi-
cation). The cytoplasmic domain of Ly49 contains a
QEVTY sequence identical to that in the human
inhibitory receptors and overlapping with the ITIM con-
sensus sequence [7,9]. Tyrosine-phosphorylated forms of
this peptide bind SHP-1 in vitro, suggesting that phospho-
rylation of Ly49 molecules on this site may recruit SHP-1
in vivo [9]. Mutation of the tyrosine in this sequence abro-
gates the ability of Ly49A to inhibit killing when
expressed in a rat NK cell line, demonstrating that
integrity of this tyrosine is essential for the delivery of the
inhibitory signal (M. Nakamura, J. Ryan and W.E.
Seaman, personal communication).
The data, while not yet conclusive, point to a critical role
for SHP-1 in the inhibition of natural killing. Taken
together, they suggest a model in which resistant target
cells induce the tyrosine phosphorylation of ITIM-like
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Figure 1
A model for the role of SHP-1 in the inhibition of natural killing. The
interactions of as yet undefined activating receptors with their ligands
(X) on target cells transduce signals via protein tyrosine kinases that
trigger cytolytic activity. Engagement of NK cell inhibitory receptors by
MHC class I molecules, however, blocks NK cell activation and
prevents killing of the target cell. Recent data suggest that
phosphorylation of tyrosines within ITIM-like sequences in the
cytoplasmic domains of inhibitory receptors recruits and activates the
protein tyrosine phosphatase SHP-1, which then inhibits the signaling
pathway for cytolytic activity.
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sequences in the cytoplasmic domains of inhibitory recep-
tors, thereby triggering an association with SHP-1 and the
activation of its phosphatase activity (Fig. 1). The inhibitory
receptors may bring SHP-1 into proximity with activating
receptors, much as CD22 and FcgRIIB bring SHP-1 into
proximity with the B-cell receptor. The interaction
between an inhibitory receptor and its MHC class I ligand
on a target cell may recruit SHP-1 to the contact site with
the target, thus promoting the co-localization of SHP-1 and
the receptors transducing signals for activation.
The substrates for SHP-1 in NK cells have yet to be identi-
fied. Engagement of inhibitory receptors prevents target
cell-induced increases in [Ca2+]i within NK cells, raising the
possibility that SHP-1 interferes with the activation of the
phospholipase C pathway [3,8]. The effects of SHP-1 on
signaling pathways would appear to be selective, because
many of the protein tyrosine phosphorylations induced by
target cells are not affected by engagement of an inhibitory
receptor [3].
Thus far, studies of inhibitory receptors for MHC class I
ligands have focused largely on NK cells, but the lessons
learned may prove to be important for T cells as well. It
has recently been appreciated that subsets of T cells
express inhibitory receptors, and that engagement of these
inhibitory receptors by their MHC class I ligands inhibits
signaling by the T-cell antigen receptor [10]. Understand-
ing the regulation of natural killing, therefore, may also tell
us much about the control of T-cell-mediated responses.
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